440
Participants
Start Date
November 19, 2024
Primary Completion Date
October 31, 2026
Study Completion Date
October 31, 2029
Moderated hypofractionated online adaptive radiotherapy
"Radiation: Moderated hypofractionated online adaptive radiotherapy (oART)+ High-dose rate (HDR) Brachytherapy~Experimental group: 43.35Gy/17F external beam radiotherapy with oART + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
Conventional radiotherapy
"Radiation: External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy~Contral group: 45Gy/25F EBRT + HDR-Brachytherapy~Drug: Concurrent Chemotherapy or immunotherapy~Weekly cisplatin 40 mg/m2 or PD-1 inhibitors"
RECRUITING
Peking Union Medical College Hospital, Beijing
Peking University Cancer Hospital & Institute
OTHER
Shandong Cancer Hospital and Institute
OTHER
Ruijin Hospital
OTHER
Peking Union Medical College Hospital
OTHER